Physician profile
Hal S Dickson
NPI 1992780894
$3,525.39
in general payments reported to CMS, 2019-2025
49 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $506 · 2020: $642 · 2021: $802 · 2022: $564 · 2023: $830 · 2024: $182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,012.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,012.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $276.19 | 2021 | |
| Abbvie INC. | $254.10 | 2020-2024 | Ubrelvy, Qulipta |
| Novartis Pharmaceuticals Corporation | $234.49 | 2019-2024 | |
| Eisai INC. | $220.66 | 2020-2023 | |
| Ucb, INC. | $189.50 | 2019-2024 | Briviact |
| Allergan, INC. | $169.26 | 2020-2021 | |
| Lilly USA, LLC | $142.84 | 2019-2024 | Amyvid, Emgality, Reyvow |
| Biogen, INC. | $121.22 | 2019-2023 | Vumerity, Tysabri |
| Amgen INC. | $102.47 | 2019-2022 | |
| Mdd US Operations, LLC | $93.77 | 2019-2023 | Apokyn |
| Jazz Pharmaceuticals INC. | $92.66 | 2019-2023 | Xywav |
| Supernus Pharmaceuticals, INC. | $90.47 | 2019-2021 | |
| Neurelis, INC. | $89.63 | 2020-2024 | Valtoco |
| Lundbeck LLC | $87.76 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $85.38 | 2019-2023 | Rytary |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hal Dickson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.